|
|
|
Volumn 12, Issue 6, 2000, Pages 317-319
|
|
What have We learned from ESPRIT? What will we learn from TARGET?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABCIXIMAB;
ANTICOAGULANT AGENT;
ANTITHROMBOCYTIC AGENT;
CLOPIDOGREL;
DRUG DERIVATIVE;
EPTIFIBATIDE;
FIBRINOGEN RECEPTOR;
FIBRINOLYTIC AGENT;
HEPARIN;
IMMUNOGLOBULIN F(AB) FRAGMENT;
MONOCLONAL ANTIBODY;
PEPTIDE;
TICLOPIDINE;
TIROFIBAN;
TYROSINE;
CLINICAL TRIAL;
COHORT ANALYSIS;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
DRUG ANTAGONISM;
EDITORIAL;
HEART INFARCTION;
HUMAN;
RANDOMIZED CONTROLLED TRIAL;
STENT;
ANTIBODIES, MONOCLONAL;
ANTICOAGULANTS;
COHORT STUDIES;
FIBRINOLYTIC AGENTS;
HEPARIN;
HUMANS;
IMMUNOGLOBULIN FAB FRAGMENTS;
MYOCARDIAL INFARCTION;
PEPTIDES;
PLATELET AGGREGATION INHIBITORS;
PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;
RANDOMIZED CONTROLLED TRIALS;
STENTS;
TICLOPIDINE;
TYROSINE;
|
|
EID: 0034198603
PISSN: 10423931
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (6)
|
|
References (0)
|
